The overarching goal of the Experimental Therapeutics (XT) Program is to bridge scientific discovery in our laboratories (bench) with clinical research (bedside) to improve clinical practice. The XT Program focuses on chemical and biological (including immune-based) approaches to cancer therapy. Recent research in the Program has advanced new agents using both approaches in mechanism-based laboratory studies. Several approaches investigated in the laboratories of our investigators have led to clinical trials for patients with cancer, including large, multi-center clinical trials led by investigators in XT. In addition to the evaluation of novel chemical and biological anti-tumor agenda, XT members are also evaluating the use of molecular and imaging methods to evaluate drug delivery and tumor response.
The XT Program aims to continue to foster robust activity in all four of the following scientific objectives:
- Discovery of new agents to validated and novel agents through rationale design, high throughput screening and detailed mechanistic preclinical studies.
- Translation of new agents and combination into first-in-human Phase I clinical trials.
- Advancing agents that show promise from the current Phase I portfolio to Phase II and Phase III trials.
- Informing future research direction through the analysis of clinical samples using state-of-the-art technologies.